
Lupin shares trade 3% higher; nears 52-week high after USFDA's approval
The drug will be manufactured at Lupin’s Pithampura plant in India, says the company.
The drug will be manufactured at Lupin’s Pithampura plant in India, says the company.
The company's revenue from operations in the Q2 of FY24, stood at ₹5,038.6 crore, up 21.5% YoY as against ₹4,145.5 crore in the same period last year.
The brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor), the company says.
The share price of the company surged as much as 4.08% to hit a 52-week high of ₹1,174.00 in early session.
The pharma major’s subsidiary has launched Propranolol LA capsules, 60 mg, 80 mg, 120 mg, and 160 mg, in Canada.
The scrip opened a gap-up at ₹834.95 on Wednesday against the closing price of the previous session at ₹829.65.
In the March quarter, the company’s profit before tax stood at ₹235.9 crore as against the net loss of ₹517.9 crore in the same period last year.
The U.S. drug regulator has issued Form 483 with ten observations for Lupin’s Pithampur unit-2 manufacturing facility.
The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.
Lupin Pharmaceuticals Inc., the U.S. arm of the drug major, is voluntarily recalling four lots of Quinapril Tablets due to the presence of nitrosamine impurity.